Dianthus Therapeutics (DNTH) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key developments and pipeline updates

• 2025 marked a transformational year with positive phase 2 data in myasthenia gravis and the in-licensing of DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL.

• Two clinical-stage products are advancing: clasiprubart (lead program) and DNTH212, with major catalysts expected in 2026 for CIDP and MMN indications.

• DNTH212's next steps include announcing three target indications in the first half of 2026 and reporting top-line results from a healthy volunteer study in the second half of 2026.

CIDP program and clinical trial strategy

• The phase 3 Captivate study in CIDP is progressing ahead of schedule, with interim responder analysis for the first 40 patients expected in Q2 2026.

• Efficacy benchmarks are set to match or exceed riliprubart, aiming for a 40%-50% responder rate and potentially reducing the trial's higher dose arm for efficiency.

• The trial design allows refractory patients and uses a rapid switch from IVIG, differentiating it from previous studies and aiming for broader applicability.

• If efficacy is confirmed, the program could neutralize competitors' time-to-market advantage and support strong market positioning.

MMN and MG program differentiation

• MMN program aims for similar or superior efficacy to empasiprubart, with advantages in dosing (subcutaneous auto-injector) and safety (no box warning expected).

• Potency data suggest the product is significantly more potent than empasiprubart, with ongoing studies to confirm if this translates to higher efficacy.

• MG program phase 2 data showed robust efficacy, especially in more severe patients, and phase 3 will implement stricter screening to control placebo response.

• Once-a-month dosing is being tested, leveraging long half-life and strong efficacy at lower inhibition levels.